Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF1 | Q13422 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.43 |
| ▸ | WIZ | O95785 | 1/20 | 0.41 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.38 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25690868 | 1.00 | IKZF1 (0.44) | IKZF1CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL25690791 | 0.90 | CRBN (0.43) | IKZF1CRBNWIZ | |
| SCHEMBL23919162 | 0.81 | HTR2A (0.45) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL22599864 | 0.80 | CRBN (0.69) | IKZF1CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL20128622 | 0.80 | CRBN (0.69) | IKZF1CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL18216837 | 0.79 | MAOA (0.44) | IKZF1CRBNWIZ | |
| SCHEMBL25690782 | 0.79 | CRBN (0.39) | IKZF1CRBNIKZF2 | |
| SCHEMBL25690787 | 0.79 | CRBN (0.39) | IKZF1CRBNIKZF2 | |
| SCHEMBL25690793 | 0.79 | CRBN (0.39) | IKZF1CRBNIKZF2 | |
| SCHEMBL25690773 | 0.79 | CRBN (0.40) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230135173-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135173-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, NR5A1, ESRRA | IKZF1 3668/4885CRBN 409/4885WIZ 4853/4885 |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | IKZF1 3057/4885CRBN 1041/4885WIZ 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.